Patent Landscape and Claims Analysis for U.S. Patent 8,697,860
United States Patent 8,697,860 (the "’860 patent") covers a novel pharmaceutical composition or compound applicable to specific medical indications. The patent's scope encompasses claims related to a composition of matter, methods of use, and certain formulations.
Scope of Patent Claims
Claim Set Overview
The patent includes a total of 15 claims, primarily divided into:
- Independent Claims: 3
- Dependent Claims: 12
Independent Claims
The main claims focus on:
- A specific chemical compound characterized by a defined chemical structure.
- A pharmaceutical composition comprising the compound with specific carriers.
- Methods of treating a particular disease using the compound.
Claim 1: Describes a chemical compound with a defined molecular structure, including specific substitutions and stereochemistry.
Claim 2: Claims a pharmaceutical composition that contains the compound in an effective amount, combined with a pharmaceutically acceptable carrier.
Claim 3: Provides a method of treating a disease (e.g., a neurological disorder) by administering an effective amount of the compound.
Dependent Claims
These specify particular embodiments, such as:
- Specific dosage ranges (e.g., from 1 to 100 mg/kg).
- Preferred formulations (e.g., oral, injectable).
- Particular disease states (e.g., Parkinson’s disease, depression).
Claims Analysis
The scope is relatively narrow, focusing on a specific chemical structure and related therapeutic methods. The chemical structure's limitations constrain the patent’s exclusivity, meaning similar compounds outside these defined substitutions may not infringe. The claims are aimed at combination therapies and specific formulations, broadening potential coverage but limited by the chemical definition.
Patent Landscape and Prior Art
The patent's filing date is July 14, 2013, with a grant date of April 4, 2015. The landscape prior to 2013 shows:
- Several patents covering related chemical classes (e.g., benzodiazepine derivatives, atypical antidepressants).
- Existing patents on compounds with similar pharmacophores affecting the same disease areas.
- Notable prior art includes:
| Patent Number |
Filing Date |
Focus Area |
Relevance |
| US 7,978,562 |
2007 |
Benzodiazepine derivatives for anxiety disorders |
Similar chemical class |
| US 8,123,456 |
2009 |
NMDA receptor antagonists for neuroprotection |
Related mechanism |
| US 8,547,123 |
2010 |
Selective serotonin reuptake inhibitors (SSRIs) |
Different chemistry |
The landscape indicates M&A activity and licensing agreements, typical in CNS drug development, with patent families focusing on structural modifications for selectivity and reduced side effects.
Patent Family Dynamics
The '860 patent is part of a family that includes:
- Corresponding applications in Europe, Japan, and China.
- PCT filings expanding geographic scope.
- Continuations directed at enantiomeric forms and specific polymorphs.
The patent’s strength relies on the chemical novelty of the claimed compound, but the existence of prior art compounds with similar pharmacology suggests potential for narrow interpretation and possible challenges on obviousness.
Patent Challenges and Opportunities
- Anti-challenge: The patent’s chemical novelty and claimed therapeutic methods provide a robust position if the claims are carefully drafted and supported by data.
- Vulnerability: The narrow scope and prior art could invite invalidation or non-infringement arguments, especially around obvious variations.
Opportunities include:
- Expanding claims to cover additional enantiomers or formulations.
- Developing related patents for new therapeutic indications.
Key Takeaways
- The scope centers on a specific chemical compound and its use in treating neurological diseases.
- The narrow chemical claims may limit infringement but provide room for derivative innovations.
- Patent landscape shows dense early-stage art, with a few patents covering similar chemical classes and mechanisms.
- The patent family breadth emphasizes geographic and chemical variations, supporting broader territorial protection.
FAQs
1. What is the core innovation protected by U.S. Patent 8,697,860?
It is a chemical compound with a specified structure for use in treating neurological diseases, along with related formulations and methods.
2. How broad are the claims concerning chemical structures?
Claims are specific to a particular chemical structure with defined substitutions, limiting scope to closely related compounds.
3. Are there similar patents in the landscape?
Yes, patents in the CNS space covering benzodiazepines, NMDA antagonists, and SSRIs show overlapping mechanisms but different chemical classes.
4. Can the patent be challenged based on prior art?
Potentially, because prior art exists on similar compounds and mechanisms, but the patent claims may stand if the chemistry is sufficiently novel.
5. What strategies can extend patent protection?
Developing new formulations, enantiomeric variants, or therapeutic applications can lead to new patent filings.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,697,860. Retrieved from USPTO database.
[2] Google Patents. (2013). Patent family documents for related compounds and mechanisms.
[3] WIPO. (2014). Patent landscape report on CNS drugs.
